Green Cross to produce once-daily influenza treatment

Green Cross Corp., a Korean drug firm, will market its investigational antiviral drug. Approval was given on August 15 by the Korea Food and Drug Administration (KFDA) for the sales of the intravenous antiviral named PeramiFlu.

Green Cross received the indication of single dose administration of 300 mg i.v. peramivir for treatment of adults with influenza A & B infection. In November 2009 af...